secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2026-09-16T01:17:38+00:00
Accession:  0001437749-26-030492
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA reclassifies NRx ketamine ANDA amendment from Major to Minor; goal date Nov 10, 2026
--------------------------------------------------------------------------------

- FDA Office of Generic Drugs reclassified NRx's preservative-free ketamine ANDA amendment from Major to Minor.
- GDUFA goal date revised to November 10, 2026; FDA cites amendment won't require substantial resource expenditure.
- CEO Jonathan Javitt praised FDA speed in advancing approval of this strategic drug-shortage product.
- Reclassification follows written FDA communication received September 15, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926030492/0001437749-26-030492-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926030492/nrxp20260915_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-030492

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer